Clinical Trial Update: ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ORIC-114 in combination with subcutaneous amivantamab for EGFR exon 20 insertion-mutant non-small cell lung cancer is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• ORIC-114

Snippet

Sponsor: ORIC Pharmaceuticals | Conditions: Solid Tumors, EGFR Exon 20 Insertion Mutations | Phase 1 | Status: RECRUITING